News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AbbVie ABBV is set to report second-quarter 2026 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's sales is pinned at $16.81 billion, while earnings per share (EPS) are estimated at $3.66. Both metrics indicate an increase …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie Inc. (ABBV) stock advanced 2.45% to $263.20 on Tuesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The company also reached a new 52-week high, exceeding its previous peak from the day before.
AbbVie Inc (ABBV) saw its stock rise by 3.35% on July 28, outperforming the Pharmaceuticals & Medical Research sector. This strong performance was attributed to robust second-quarter earnings, significant growth in its immunology drugs Skyrizi and Rinvoq, and positive late-stage clinical trial data in …
Sharemaestro market context Trend signal active 52 weeks +9.6%Abbott Laboratories is focusing on continuous glucose monitoring, oncology diagnostics, and advanced cardiovascular treatment as key innovation themes for long-term growth. The company has seen strong sales in these areas, including its FreeStyle Libre, despite facing risks like reimbursement challenges, integration demands from acquisitions, …
Barclays has increased its price target for AbbVie (ABBV) to $300 from $275, while reiterating an Overweight rating on the stock. The adjustment reflects an updated outlook from the analytical firm regarding the pharmaceutical company's future performance. AbbVie specializes in therapeutic drug research and …
Freenome Inc. has received FDA approval for its SimpleScreen CRC, a blood test for early detection of colorectal cancer, which will be marketed by Abbott starting this fall. This marks a significant achievement for the company, following its public offering for $300 million.
The Northern District of Illinois ruled that Abbott Laboratories did not commit securities fraud regarding its tainted baby formula. This decision indicates that the allegations did not meet the legal threshold for securities fraud. The case was brought against the company concerning the public …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) has secured exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, a newly FDA approved blood based colorectal cancer screening test. …
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%Sarepta Therapeutics has appointed Michael Severino, former vice chairman at AbbVie and CEO of Tessera Therapeutics, as its new chief executive, effective Tuesday. Severino replaces Doug Ingram, who is retiring due to family health issues. Severino will face the challenge of navigating commercial realities …
Sarepta Therapeutics has appointed Michael Severino, an executive with experience at AbbVie and Amgen and most recently Tessera Therapeutics, as its new CEO, effective July 28. Severino faces the challenge of turning around Sarepta's fortunes, as the company has lost significant market value over …
Sarepta Therapeutics has appointed Michael Severino, formerly of Tessera Therapeutics and AbbVie, as its new CEO, succeeding Doug Ingram. Severino takes the helm at a critical juncture as Sarepta awaits two key FDA decisions for its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys …
AbbVie Inc. (ABBV) stock has reached a new all-time high of $261.71, reflecting a 40.53% total return over the past year. Despite being considered slightly overvalued by InvestingPro analysis, the company demonstrates strong financial health with 9.5% revenue growth. Upcoming earnings on July 31st …
Sharemaestro market context Trend signal active 52 weeks +16.4%AbbVie (ABBV) recently acquired Apogee Therapeutics for $10.9 billion, a move that is expected to dilute adjusted EPS until 2032 but aims for a "mega blockbuster" drug, zumilokibart, targeting over $10 billion in peak sales. Despite the near-term dilution, AbbVie stock has largely recovered …
Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%Sarepta Therapeutics has appointed Michael Severino, former Tessera Therapeutics CEO and a longtime AbbVie executive, as its new chief executive, effective July 28. Severino will succeed Doug Ingram, who is stepping down after leading Sarepta since 2017 but will remain in an advisory role …
This article from Stock Traders Daily analyzes Abbvie Inc. (ABBV) and its impact on rotational strategy timing. It highlights a neutral sentiment for ABBV across all horizons, suggesting a wait-and-see approach, and identifies no resistance levels above the current price, indicating potential upside. The …
Abbott Laboratories (ABT) experienced a decline in performance in Q2 2026, primarily due to lowered full-year guidance after the Exact Sciences acquisition, headwinds in its Nutrition and Diagnostics segments, and ongoing litigation concerns related to its preterm infant formula. These issues overshadowed strong organic …
Abbott Laboratories (ABT) reported a stronger second quarter with an earnings beat and raised its full-year profit outlook, driven by growth in medical devices and cancer diagnostics. Despite these positive updates and a diversified business model providing support, the stock's valuation offers limited upside …
This Zacks Investment Ideas feature highlights General Motors, Abbott Laboratories, and Johnson & Johnson, all of which posted strong Q2 earnings and raised their guidance. These guidance upgrades are considered a bullish indicator, often leading to positive share reactions and reflecting improving business fundamentals, …
Abbott Laboratories' stock (ABT) is trading steadily, supported by diversified revenue streams from diagnostics, medical devices, nutrition, and established pharmaceuticals. Despite a decline in COVID-19 testing revenue, core businesses like continuous glucose monitoring and cardiovascular devices are driving growth, leading to resilient earnings and …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%AbbVie (ABBV) may be 3% undervalued despite a recent setback in the Phase 3 EPCORE DLBCL-1 trial for its drug epcoritamab. The company's diverse pipeline and strong cash generation suggest potential for future growth, with a fair value estimated at $266.89 against a last …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie Inc. is managing a transition as its blockbuster drug Humira faces declining sales due to biosimilar competition. The company is actively offsetting this revenue loss with the strong growth of newer immunology drugs, Skyrizi and Rinvoq, which are showing double-digit percentage growth. Investors …
Schubert Jonckheer & Kolbe LLP is investigating a data breach impacting Abbott Laboratories and its subsidiary Exact Sciences Corporation. An unauthorized third party, allegedly ShinyHunters, accessed legacy cancer diagnostics systems in July 2026, potentially exfiltrating sensitive patient information including names, contact details, dates of …
The article poses a question about whether investors should pay attention to AbbVie stock's momentum. However, the provided content is largely navigational, legal disclaimers, and technical limitations of an interactive model, without any actual article text or financial analysis regarding AbbVie. It does not …
Abbott Laboratories (ABT) is considered 14% undervalued despite mixed Q2 2026 earnings, which showed increased sales but lower net income year-over-year. The company's stock has seen short-term gains, rising 13.9% over 30 days, reflecting a reset in investor expectations and a focus on future …
Sharemaestro market context Price above Trend Line 52 weeks -14.8% · Next-week setup positive 55.5%AbbVie Inc. (NYSE:ABBV) stock is projected to move by 4.2% based on options data ahead of its July 31 earnings release. Historically, the stock's actual movement has often exceeded the implied move from options. The article details past earnings announcement performances, noting instances where …
A federal judge in Chicago has dismissed a lawsuit against Abbott Laboratories that accused the company of defrauding shareholders regarding its 2022 infant formula recall. The judge stated that despite a lengthy complaint, shareholders failed to adequately present claims against Abbott or individual defendants.
AbbVie (ABBV) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended June 2026, with results anticipated on July 31. The consensus EPS estimate is $3.66 per share (+23.2% year-over-year) and revenues are projected at $16.81 billion (+9%). …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%This article summarizes the "Final Trades" segment on CNBC, highlighting stock picks from various financial experts. Recommendations include AbbVie (ABBV) with a raised price target, Transocean (RIG) ahead of earnings, Cerebras Systems (CBRS) due to a new cybersecurity partnership with CrowdStrike (CRWD), and Netflix …
Search by ticker symbol or company name and select a result to open its chart.